Search Results - "Petrylak, D P"

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy by de Bono, J.S., Molife, L.R., Sonpavde, G., Maroto, J.P., Calvo, E., Cartwright, T.H., Loesch, D.M., Feit, K., Das, A., Zang, E.A., Wanders, J., Agoulnik, S., Petrylak, D.P.

“…Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane…”
Get full text

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up by Fradet, Y., Bellmunt, J., Vaughn, D.J., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Nam, K., Frenkl, T.L., Perini, R.F., de Wit, R., Bajorin, D.F.

“…Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a…”
Get full text

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study by Necchi, A., Joseph, R.W., Loriot, Y., Hoffman-Censits, J., Perez-Gracia, J.L., Petrylak, D.P., Derleth, C.L., Tayama, D., Zhu, Q., Ding, B., Kaiser, C., Rosenberg, J.E.

“…Conventional criteria for tumor progression may not fully reflect the clinical benefit of immunotherapy or appropriately guide treatment decisions. The phase…”
Get full text

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group by BUBLEY, G. J, CARDUCCI, M, HUSSAIN, M, KAPLAN, R, MYERS, C, OH, W, PETRYLAK, D. P, REED, E, ROTH, B, SARTOR, O, SCHER, H, SIMONS, J, DAHUT, W, SINIBALDI, V, SMALL, E. J, SMITH, M. R, TRUMP, D. L, VOLLMER, R, WILDING, G, DAWSON, N, DALIANI, D, EISENBERGER, M, FIGG, W. D, FREIDLIN, B, HALABI, S, HUDES, G

“…Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic…”
Get full text

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma by Rosenberg, J.E., Powles, T., Sonpavde, G.P., Loriot, Y., Duran, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Mamtani, R., Wu, C., Matsangou, M., Campbell, M., Petrylak, D.P.

“…This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over a median follow-up of ∼2 years from EV-301…”
Get full text

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up by Balar, A.V., Castellano, D.E., Grivas, P., Vaughn, D.J., Powles, T., Vuky, J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Necchi, A., Petrylak, D.P., Plimack, E.R., Xu, J.Z., Imai, K., Moreno, B.H., Bellmunt, J., de Wit, R., O’Donnell, P.H.

“…Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (UC). Long-term follow-up is necessary to confirm durability of response…”
Get full text

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer by PETRYLAK, D. P, MACARTHUR, R. B, ZUECH, N, SAWCZUK, I, BENSON, M, OLSSON, C. A, O'CONNOR, J, SHELTON, G, JUDGE, T, BALOG, J, PFAFF, C, BAGIELLA, E, HEITJAN, D, FINE, R

“…To evaluate the toxicity, efficacy, and pharmacokinetics of docetaxel when combined with oral estramustine and dexamethasone in a phase I study in patients…”
Get full text

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer by DiPaola, R S, Plante, M, Kaufman, H, Petrylak, D P, Israeli, R, Lattime, E, Manson, K, Schuetz, T

“…Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic…”
Get full text

Docetaxel (Taxotere) in hormone-refractory prostate cancer by Petrylak, D P

“…Considerations of both molecular biology and data from in vitro studies suggest a potential for the combination of docetaxel (Taxotere; Rhône-Poulenc Rorer,…”
Get more information

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone by Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C.J., Petrylak, D.P., Attard, G., Shen, L., Fizazi, K., de Bono, J.

“…Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II…”
Get full text

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer by Halabi, S, Dutta, S, Tangen, C M, Rosenthal, M, Petrylak, D P, Thompson, Jr, I M, Chi, K N, De Bono, J S, Araujo, J C, Logothetis, C, Eisenberger, M A, Quinn, D I, Fizazi, K, Morris, M J, Higano, C S, Tannock, I F, Small, E J, Kelly, W K

“…We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration-resistant prostate…”
Get full text

Chemotherapy for advanced hormone refractory prostate cancer by Petrylak, Daniel P

“…Men with metastatic prostate cancer treated with androgen ablation respond rapidly and often dramatically to therapy, with improvement of bone pain, regression…”
Get full text

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer by Bellmunt, J., Eigl, B.J., Senkus, E., Loriot, Y., Twardowski, P., Castellano, D., Blais, N., Sridhar, S.S., Sternberg, C.N., Retz, M., Pal, S., Blumenstein, B., Jacobs, C., Stewart, P.S., Petrylak, D.P.

“…Five-year survival of patients with inoperable, advanced urothelial carcinoma treated with the first-line chemotherapy is 5%–15%. We assessed whether the Hsp27…”
Get full text

Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression by Sternberg, C.N., Bellmunt, J., Nishiyama, H., Petrylak, D.P., Quinn, D.I., Nakajima, K., Lu, C., Holynskyj, A.

Get full text

Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point by SMALL, E. J, LEW, D, REDMAN, B. G, PETRYLAK, D. P, HAMMOND, N, GROSS, H. M, EASTHAM, J. A, CRAWFORD, E. D

“…The combination of paclitaxel and carboplatin for the treatment of advanced transitional-cell carcinoma (TCC) of the urothelium has promising activity and…”
Get full text

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) by Petrylak, D.P., Rosenberg, J., Duran, I., Loriot, Y., Sonpavde, G., Wu, C., Gartner, E., Melhem-Bertrandt, A., Powles, T.

Get full text

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy by Rosenberg, J.E., Balar, A., O’Donnell, P.H., Heath, E.I., Hahn, N.M., Cavazos, N.M., Melhem-Bertrandt, A., Petrylak, D.P.

Get full text

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC) by Morris, M.J., Vogelzang, N.J., Sartor, O., Armour, A., Messmann, R., Groaning, M., Robarts, A., Tolcher, A.W., Gordon, M., Babiker, H.M., Kuo, P., Kearney, M., Jendrisak, A., Wang, Y., Landers, M., Petrylak, D.P.

Get full text

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer by Petrylak, D P, Macarthur, R, O'Connor, J, Shelton, G, Weitzman, A, Judge, T, England-Owen, C, Zuech, N, Pfaff, C, Newhouse, J, Bagiella, E, Hetjan, D, Sawczuk, I, Benson, M, Olsson, C

“…Evaluation of the combined regimen of estramustine and docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) in men with hormone-refractory prostate…”
Get more information

Rapid in Vivo Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging by KLINE, R. P, WU, E. X, PETRYLAK, D. P, SZABOLCS, M, ALDERSON, P. O, WEISFELDT, M. L, CANNON, P, KATZ, J

“…A novel pulse sequence strategy uses sodium magnetic resonance imaging to monitor the response to chemotherapy of mouse xenograft tumors propagated from human…”
Get full text